Combination of expression levels of miR-21 and miR-126 is associated with cancer-specific survival in clear-cell renal cell carcinoma

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Vergho, Daniel ^a   Kneitz, Susanne ^b   Rosenwald, Andreas ^b   Scherer, Charlotte ^a   Spahn, Martin ^c   Burger, Maximilian ^a   Riedmiller, Hubertus ^a   Kneitz, Burkhard ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Biomarker; Kidney cancer; miR 126; miR 21; miRNA; Profiling; Prognosis; RCC; Renal cell carcinoma; Tumour markers

Indexed keywords

MICRORNA 126; MICRORNA 21;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER SPECIFIC SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; COMBINED RISK SCORE; CONTROLLED STUDY; DOWN REGULATION; FEASIBILITY STUDY; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; UPREGULATION; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; GENE EXPRESSION PROFILING; HUMANS; KIDNEY NEOPLASMS; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; NEPHRECTOMY; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84892746790     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-25     Document Type: Article

References (31)

1. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010, 58(3):398-406. 10.1016/j.eururo.2010.06.032, 20633979.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108. 10.3322/canjclin.55.2.74, 15761078.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006, 56(2):106-130. 10.3322/canjclin.56.2.106, 16514137.
4. Hui A, How C, Ito E, Liu FF. Micro-RNAs as diagnostic or prognostic markers in human epithelial malignancies. BMC Cancer 11:500.
5. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 2011, 59(5):671-681. 10.1016/j.eururo.2011.01.044, 21296484.
6. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J, Rodriguez R, et al. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 2009, 69(18):7165-7169. 10.1158/0008-5472.CAN-09-1448, 2861586, 19738047.
7. Faragalla H, Youssef YM, Scorilas A, Khalil B, White NM, Mejia-Guerrero S, Khella H, Jewett MA, Evans A, Lichner Z, et al. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. J Mol Diagn 2012, 14(4):385-392. 10.1016/j.jmoldx.2012.02.003, 22580180.
8. Juan D, Alexe G, Antes T, Liu H, Madabhushi A, Delisi C, Ganesan S, Bhanot G, Liou LS. Identification of a microRNA panel for clear-cell kidney cancer. Urology 2010, 75(4):835-841. 10.1016/j.urology.2009.10.033, 20035975.
9. Zaman MS, Shahryari V, Deng G, Thamminana S, Saini S, Majid S, Chang I, Hirata H, Ueno K, Yamamura S, et al. Up-regulation of microRNA-21 correlates with lower kidney cancer survival. PLoS One 2012, 7(2):e31060. 10.1371/journal.pone.0031060, 3275568, 22347428.
10. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY, Srivastava D. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008, 15(2):272-284. 10.1016/j.devcel.2008.07.008, 2604134, 18694566.
11. Meister J, Schmidt MH. miR-126 and miR-126*: new players in cancer. Sci World J 2010, 10:2090-2100.
12. Youssef YM, White NM, Grigull J, Krizova A, Samy C, Mejia-Guerrero S, Evans A, Yousef GM. Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol 2011, 59(5):721-730. 10.1016/j.eururo.2011.01.004, 21272993.
13. Sasahira T, Kurihara M, Bhawal UK, Ueda N, Shimomoto T, Yamamoto K, Kirita T, Kuniyasu H. Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer. Br J Cancer 2012, 107(4):700-706. 10.1038/bjc.2012.330, 3419968, 22836510.
14. Yang J, Lan H, Huang X, Liu B, Tong Y. MicroRNA-126 inhibits tumor cell growth and its expression level correlates with poor survival in non-small cell lung cancer patients. PLoS One 2012, 7(8):e42978. 10.1371/journal.pone.0042978, 3416793, 22900072.
15. Hansen TF, Sorensen FB, Lindebjerg J, Jakobsen A. The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer. BMC Cancer 2012, 12:83. 10.1186/1471-2407-12-83, 3311029, 22397399.
16. Khella HW, White NM, Faragalla H, Gabril M, Boazak M, Dorian D, Khalil B, Antonios H, Bao TT, Pasic MD, et al. Exploring the role of miRNAs in renal cell carcinoma progression and metastasis through bioinformatic and experimental analyses. Tumour Biol 2012, 33(1):131-140. 10.1007/s13277-011-0255-5, 22086373.
17. Slaby O, Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R, Svoboda M, Vyzula R. Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes Cancer 2012, 51(7):707-716. 10.1002/gcc.21957, 22492545.
18. Spahn M, Kneitz S, Scholz CJ, Stenger N, Rudiger T, Strobel P, Riedmiller H, Kneitz B. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 2010, 127(2):394-403.
19. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, Levy R. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004, 350(18):1828-1837. 10.1056/NEJMoa032520, 15115829.
20. Ribal MJ. Molecular profiling of renal cancer: the journey to clinical application. Eur Urol 2011, 59(5):731-733. 10.1016/j.eururo.2011.01.039, 21296486.
21. Heinzelmann J, Henning B, Sanjmyatav J, Posorski N, Steiner T, Wunderlich H, Gajda MR, Junker K. Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol 2011, 29(3):367-373. 10.1007/s00345-010-0633-4, 21229250.
22. Slaby O, Jancovicova J, Lakomy R, Svoboda M, Poprach A, Fabian P, Kren L, Michalek J, Vyzula R. Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J Exp Clin Cancer Res 2010, 29:90. 10.1186/1756-9966-29-90, 2907341, 20609231.
23. White NM, Khella HW, Grigull J, Adzovic S, Youssef YM, Honey RJ, Stewart R, Pace KT, Bjarnason GA, Jewett MA, et al. miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br J Cancer 2011, 105(11):1741-1749. 10.1038/bjc.2011.401, 3242591, 22033272.
24. Wotschofsky Z, Liep J, Meyer HA, Jung M, Wagner I, Disch AC, Schaser KD, Melcher I, Kilic E, Busch J, et al. Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomas. Int J Biol Sci 2012, 8(10):1363-1374. 3492794, 23139634.
25. Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL, Dai B, Zhu YP, Shen YJ, Shi GH, Ye DW. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 2011, 71(3):326-331. 10.1002/pros.21246, 20842666.
26. Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, Li Y. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 2008, 27(31):4373-4379. 10.1038/onc.2008.72, 18372920.
27. Zhang A, Liu Y, Shen Y, Xu Y, Li X. miR-21 modulates cell apoptosis by targeting multiple genes in renal cell carcinoma. Urology 2011, 78(2):474-e413-479.
28. Png KJ, Halberg N, Yoshida M, Tavazoie SF. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 2011, 481(7380):190-194. 10.1038/nature10661, 22170610.
29. Donnem T, Lonvik K, Eklo K, Berg T, Sorbye SW, Al-Shibli K, Al-Saad S, Andersen S, Stenvold H, Bremnes RM, et al. Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer: coexpression with vascular endothelial growth factor-A predicts poor survival. Cancer 2011, 117(14):3193-3200. 10.1002/cncr.25907, 21264844.
30. Wu X, Weng L, Li X, Guo C, Pal SK, Jin JM, Li Y, Nelson RA, Mu B, Onami SH, et al. Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One 2012, 7(5):e35661. 10.1371/journal.pone.0035661, 3356334, 22623952.
31. Sun M, Shariat SF, Cheng C, Ficarra V, Murai M, Oudard S, Pantuck AJ, Zigeuner R, Karakiewicz PI. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol 2010, 60(4):644-661.